- Medical - Devices
- Healthcare
-
4.85
EPS
-
22.41
P/E
-
22.1B
MARKET CAP
-
0.44%
DIV YIELD
Company Overview
345 EAST MAIN STREET,WARSAW IN 46580,5742676131
CEO
Mr. Ivan Tornos
Employess
18000
Sector
Healthcare
Industry
Medical - Devices
Website
https://www.zimmerbiomet.com
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest toss facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as robotic, surgical and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
Next Earnings Date
Nov. 5, 2024
Ex Dividends date
Jul. 31, 2024
Dividend Date
June 26, 2024
YTD Performance
-10.54%
Fiscal Year End
12-31
IPO Date
2001-07-25
Growth Rates
(avg. rate of change) | 10 years | 5 years | 3 years | 1 year |
---|---|---|---|---|
Sales/Revenue | 4.81% | -1.40% | 1.72% | 6.55% |
EPS | 0.90% | 35.93% | 111.34% | 253.24% |
Equity | 7.08% | 2.05% | 0.76% | 3.82% |
Cash | -9.11% | -5.19% | -19.67% | 10.67% |
Return On Capital (ROIC) | 5.77% | 4.84% | 5.17% | 7.28% |
Debt
year (millions) | 2023 | 2022 | 2021 | 2020 | 2019 |
---|---|---|---|---|---|
Short Term Debt | 953 | 544 | 1,610 | 500 | 1,500 |
Long Term Debt | 4,870 | 5,150 | 5,470 | 7,630 | 6,720 |
LT Finance Leases | 174 | 167 | 175 | 218 | 216 |
Shares Outstanding | 209 | 210 | 209 | 207 | 205 |
Market Cap | 25,400 | 26,700 | 25,700 | 30,900 | 29,800 |
Price
News
Here's Why Zimmer Biomet (ZBH) is a Strong Value Stock
1 monthThe Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
zacks.comZimmer Biomet (ZBH) Beats on Q2 Earnings, Cuts Revenue View
1 monthZimmer Biomet's (ZBH) strategic expansion of international business contributes to the top line in the second quarter.
zacks.comZimmer (ZBH) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
1 monthAlthough the revenue and EPS for Zimmer (ZBH) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
zacks.comZimmer Biomet (ZBH) Tops Q2 Earnings and Revenue Estimates
1 monthZimmer Biomet (ZBH) came out with quarterly earnings of $2.01 per share, beating the Zacks Consensus Estimate of $1.98 per share. This compares to earnings of $1.82 per share a year ago.
zacks.comZimmer Biomet beats profit estimates on strong demand for medical devices
1 monthZimmer Biomet Holdings beat Wall Street estimates for second-quarter profit on Wednesday, driven by robust demand for its devices used in joint reconstruction procedures.
reuters.comZimmer Biomet Announces Second Quarter 2024 Financial Results
1 monthSecond quarter net sales of $1.942 billion increased 3.9% and 5.6% on a constant currency1 basis Second quarter diluted earnings per share were $1.18; adjusted1 diluted earnings per share were $2.01 The Company updates 2024 reported revenue guidance due to currency expectations and reaffirms 2024 constant currency revenue growth and adjusted1 earnings per share financial guidance WARSAW, Ind. , Aug. 7, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended June 30, 2024.
prnewswire.comExploring Analyst Estimates for Zimmer (ZBH) Q2 Earnings, Beyond Revenue and EPS
2 monthsBeyond analysts' top -and-bottom-line estimates for Zimmer (ZBH), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2024.
zacks.com10 Beaten-Up Blue Chips With Serious Turnaround Potential
2 monthsHere is my list of blue-chip stocks to research for a buy-on-weakness strategy. Each has the potential to dip by -10% to -20%, given the July S&P 500 correction expands into a more serious bear market. The goal is to purchase stocks at low future PEG Ratios and EV to EBITDA readings for +50% to +100% total returns by the end of 2025.
seekingalpha.com3 Healthcare Stocks to Buy at a 52-Week Low in July
2 monthsFinding value in this market is difficult because the S&P 500 has increased over 50% since its bottom in October 2022. Certainly, you won't find it in technology or mega caps, which have soared due to the AI craze.
investorplace.comHere's How Zimmer Biomet (ZBH) is Poised Ahead of Q2 Earnings
2 monthsZimmer Biomet (ZBH) is expected to have witnessed procedure volume recovery banking on strategic product launches in the second quarter.
zacks.comWhy Zimmer Biomet (ZBH) is a Top Value Stock for the Long-Term
2 monthsWondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
zacks.comHere's Why Zimmer Biomet (ZBH) is a Strong Momentum Stock
2 monthsThe Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
zacks.com